Reuters logo
BRIEF-Cellectar Biosciences says CLR 131 achieved median overall survival of 22.5 months to date after single dose infusion of 12.5mci/m in multiple myeloma​ patients
2017年8月8日 / 下午12点46分 / 2 个月前

BRIEF-Cellectar Biosciences says CLR 131 achieved median overall survival of 22.5 months to date after single dose infusion of 12.5mci/m in multiple myeloma​ patients

Aug 8 (Reuters) - Cellectar Biosciences Inc

* Cellectar Biosciences - CLR 131 achieved median overall survival of 22.5 months to date after single dose infusion of 12.5mci/m in multiple myeloma​ patients Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below